Evidence map›Paper›PMID 39606248›Full record

ReviewFrontiers in immunology2024

Autoimmune disease: a view of epigenetics and therapeutic targeting.

Siqi Mu, Wanrong Wang, Qiuyu Liu, Naiyu Ke, Hao Li, Feiyang Sun, Jiali Zhang, Zhengwei Zhu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Review
  2. Review
  3. mMolecular medicine reports · 2026
    Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Biological multi-omics approaches to next-generation biomarkers in immune-related disorders and malignancies: An overview.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Trojan Horse Strategy: How Biomimetic Nanomedicine Remodels the Tumor Microenvironment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Siqi MuDepartment of Dermatology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Wanrong WangDepartment of Skin Genetics, Anhui Province Laboratory of Inflammation and Immune Mediated Diseases, Hefei, Anhui, China.
Qiuyu LiuFirst Clinical Medical College, Anhui Medical University, Hefei, Anhui, China.
Naiyu KeDepartment of Ophthalmology, First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Hao LiDepartment of Urology, First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Feiyang SunFirst Clinical Medical College, Anhui Medical University, Hefei, Anhui, China.
Jiali ZhangDepartment of Dermatology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Zhengwei ZhuDepartment of Dermatology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autoimmune diseases comprise a large group of conditions characterized by a complex pathogenesis and significant heterogeneity in their clinical manifestations. Advances in sequencing technology have revealed that in addition to genetic susceptibility, various epigenetic mechanisms including DNA methylation and histone modification play critical roles in disease development. The emerging field of epigenetics has provided new perspectives on the pathogenesis and development of autoimmune diseases. Aberrant epigenetic modifications can be used as biomarkers for disease diagnosis and prognosis. Exploration of human epigenetic profiles revealed that patients with autoimmune diseases exhibit markedly altered DNA methylation profiles compared with healthy individuals. Targeted cutting-edge epigenetic therapies are emerging. For example, DNA methylation inhibitors can rectify methylation dysregulation and relieve patients. Histone deacetylase inhibitors such as vorinostat can affect chromatin accessibility and further regulate gene expression, and have been used in treating hematological malignancies. Epigenetic therapies have opened new avenues for the precise treatment of autoimmune diseases and offer new opportunities for improved therapeutic outcomes. Our review can aid in comprehensively elucidation of the mechanisms of autoimmune diseases and development of new targeted therapies that ultimately benefit patients with these conditions.

Indexed as

Autoimmune DiseasesDNA MethylationEpigenesis, GeneticAnimalsHistone Deacetylase InhibitorsHumansMolecular Targeted TherapyHistone Deacetylase Inhibitorsautoimmune diseaseDNA methylationepigenetichistone modificationRNA modificationsystemic lupus erythematosus

Identifiers

PMID39606248
PMCPMC11599216

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.